PMID- 21916927
OWN - NLM
STAT- MEDLINE
DCOM- 20120907
LR  - 20220311
IS  - 1365-2990 (Electronic)
IS  - 0305-1846 (Linking)
VI  - 38
IP  - 4
DP  - 2012 Jun
TI  - Prevalence and severity of cerebral amyloid angiopathy: a population-based study 
      on very elderly Finns (Vantaa 85+).
PG  - 329-36
LID - 10.1111/j.1365-2990.2011.01219.x [doi]
AB  - BACKGROUND: Cerebral amyloid angiopathy (CAA) is frequent in patients with 
      Alzheimer's disease while its prevalence in different populations is variable. We 
      investigated the prevalence and severity of CAA in a very elderly Finnish 
      population. METHODS: Neuropathological investigation was performed on 306 
      subjects from the population-based Vantaa 85+ Study (253 women, 53 men, mean age 
      at death 92.3 years). The presence of CAA was analysed in six brain regions by 
      using Congo red and immunohistochemistry with an antibody against amyloid beta 
      peptide. The severity of CAA was assessed by counting the percentage of the 
      CAA-positive blood vessels. RESULTS: In total, 69.6% of the participants (170 
      women, 43 men) had CAA, with median severity of 1.0%, inter-quartile range (IQR) 
      0-5.4% and range 0-72.7%. CAA was more prevalent (81.1% vs. 67.2%; P = 0.046) and 
      severe (median 2.7%, IQR 0.4-7.5%, range 0-72.7%) in the men than in the women 
      (median 1.0%, IQR 0-4.6%, range 0-52.8%; P = 0.004). Parietal lobe showed the 
      highest prevalence (57.8%) whereas the severity was highest (median 1.0%, IQR 
      0-6.0%, range 0-77%) in the frontal lobe. Prevalence of CAA in the six regions 
      was variable, but the severity indices between those regions correlated highly 
      (P < 0.001 for all regions). Meningeal CAA was more prevalent (69.5%) than 
      cortical (59.3%; P < 0.001). CONCLUSION: CAA was highly prevalent, albeit mild, 
      in the very old. The prevalence and severity of CAA were found to be highest in 
      the frontal and parietal lobes respectively - independent of the staining method 
      used (Congo red or amyloid beta peptide).
CI  - (c) 2011 The Authors. Neuropathology and Applied Neurobiology (c) 2011 British 
      Neuropathological Society.
FAU - Tanskanen, M
AU  - Tanskanen M
AD  - Department of Pathology, Haartman Institute, University of Helsinki and HUSLAB, 
      Haartmaninkatu 3, Helsinki, Finland. maarit.tanskanen@helsinki.fi
FAU - Makela, M
AU  - Makela M
FAU - Myllykangas, L
AU  - Myllykangas L
FAU - Notkola, I-L
AU  - Notkola IL
FAU - Polvikoski, T
AU  - Polvikoski T
FAU - Sulkava, R
AU  - Sulkava R
FAU - Kalimo, H
AU  - Kalimo H
FAU - Paetau, A
AU  - Paetau A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Neuropathol Appl Neurobiol
JT  - Neuropathology and applied neurobiology
JID - 7609829
RN  - 0 (Coloring Agents)
RN  - 3U05FHG59S (Congo Red)
SB  - IM
MH  - Aged, 80 and over
MH  - Brain/blood supply/*pathology
MH  - Cerebral Amyloid Angiopathy/*epidemiology/*pathology
MH  - Coloring Agents
MH  - Congo Red
MH  - Female
MH  - Finland/epidemiology
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Prevalence
EDAT- 2011/09/16 06:00
MHDA- 2012/09/08 06:00
CRDT- 2011/09/16 06:00
PHST- 2011/09/16 06:00 [entrez]
PHST- 2011/09/16 06:00 [pubmed]
PHST- 2012/09/08 06:00 [medline]
AID - 10.1111/j.1365-2990.2011.01219.x [doi]
PST - ppublish
SO  - Neuropathol Appl Neurobiol. 2012 Jun;38(4):329-36. doi: 
      10.1111/j.1365-2990.2011.01219.x.